Oncology – Breast
RCT | Gemcitabine vs. Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.
14 Jul, 2022 | 12:10h | UTC
Commentary on Twitter
Gemcitabine or nab-paclitaxel in combination with cisplatin as first-line treatment in patients with metastatic triple-negative breast cancer: results of a randomized phase 3 trial.https://t.co/RKZYdLRbHq#CancerResearch @natrescancer pic.twitter.com/CrCOCJ2HMu
— Nature Communications (@NatureComms) July 13, 2022
Long-term analysis of a Phase 2 RCT | Fulvestrant plus capivasertib vs. placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor-positive, HER2-negative breast cancer.
11 Jul, 2022 | 11:48h | UTCNews Release: New phase of breast cancer drug trial provides fresh hope for patients with incurable disease – Cardiff University
M-A | Risk factors for anthracycline-induced cardiotoxicity in breast cancer treatment.
7 Jul, 2022 | 12:17h | UTC
RCT: Atezolizumab with neoadjuvant anti–human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2–positive early breast cancer.
1 Jul, 2022 | 10:28h | UTCCommentary: Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer – OncLive
Commentary on Twitter
Presented at #ESMO VP6, IMpassion050 is now published on JCO. The addition of atezo to neoadjuvant ddAC-T+HP doesn’t increase pCR rates in HER2+ EBC, neither in ITT (left) nor PD-L1+ (right). Significant increase in toxicity with atezo, including 5 deaths.https://t.co/fL6mEjKTTS pic.twitter.com/2fYStkh8Zt
— Paolo Tarantino (@PTarantinoMD) June 28, 2022
ASCO Guideline Update: Biomarkers for systemic therapy in metastatic breast cancer.
29 Jun, 2022 | 11:40h | UTC
Commentary on Twitter
‼️ ? @ASCO guideline update published in #JCO by @lynnhenrymd et al: Biomarkers for #SystemicTherapy in Metastatic #BreastCancer ➡️ https://t.co/qAzT9WNKTF #bcsm #biomarkers @AngieDemichele pic.twitter.com/3WtAt8TK5w
— Journal of Clinical Oncology (@JCO_ASCO) June 27, 2022
Systematic Review: Trastuzumab Deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies.
29 Jun, 2022 | 10:59h | UTC
Cohort Study: Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer.
27 Jun, 2022 | 11:09h | UTCPrognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Is #HER2low a distinct BC subtype? Among >5000 pts from DFCI/Brigham, we found no relevant difference between HER2-low & HER2-0 BC. ER-exp determined disease behavior & was positively associated with HER2-low exp. Huge thanks to @stolaney1 & all coauthors!https://t.co/OfGT8LS2pH pic.twitter.com/uFxXGvOI8S
— Paolo Tarantino (@PTarantinoMD) June 23, 2022
Phase II RCT: Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer.
22 Jun, 2022 | 10:49h | UTCSwitch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
NCCN Updated Guideline: Breast cancer.
20 Jun, 2022 | 01:24h | UTC
Cohort Study: Association of screening with digital breast tomosynthesis vs. digital mammography with risk of interval invasive and advanced breast cancer.
17 Jun, 2022 | 11:09h | UTCAssociation of Screening With Digital Breast Tomosynthesis vs Digital Mammography With Risk of Interval Invasive and Advanced Breast Cancer – JAMA (free for a limited period)
Editorial: Digital Breast Tomosynthesis and Detection of Interval Invasive and Advanced Breast Cancers – JAMA (free for a limited period)
News Release: 3-D Mammography Technique Benefits Some Women, Not All – University of California San Francisco
Regional lymphadenopathy following COVID-19 vaccination in patients with or suspicious of breast cancer: a quick summary of current key facts and recommendations.
14 Jun, 2022 | 11:07h | UTCRelated:
2 Case Series and Guidance | Lymphadenopathy in COVID-19 Vaccine Recipients
Circulating tumor DNA and late recurrence in high-risk hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer.
13 Jun, 2022 | 07:35h | UTCCommentary: Tumor DNA Assay Portends Metastatic Breast Cancer Recurrence Months in Advance — First evidence for patients in late adjuvant setting, years after initial diagnosis – MedPage Today (free registration required)
Commentary on Twitter
103 women in long-term remission from high-risk HR+/HER2- breast cancer had customized monitoring of recurrence based on ctDNA seq for tumour-associated mut. Among 8 pts MRD+ pts, 6 developed distant recurrence at a median 12.4 mo after ctDNA positivity https://t.co/aX1ruLCSbb
— NatureRevClinOncol (@NatRevClinOncol) June 9, 2022
Cohort Study: Long-term quality of life in patients with breast cancer after breast conservation vs mastectomy and reconstruction.
9 Jun, 2022 | 10:30h | UTCLong-term Quality of Life in Patients With Breast Cancer After Breast Conservation vs Mastectomy and Reconstruction – JAMA Surgery (link to abstract – $ for full-text)
Commentaries:
Long-Term QOL Examined for Surgical Choices in Breast Cancer – HealthDay
Commentary on Twitter
Survey of #breastcancer survivors after treatment found:
1. Breast satisfaction and physical well-being similar with lumpectomy+rads or mastectomy+reconstruction (no rads)
2. Psychosocial well-being and sexual well-being better with lumpectomy+rads https://t.co/tPh9Pt4gYx— JAMA Surgery (@JAMASurgery) April 14, 2022
#ASCO22 – RCT: Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer.
6 Jun, 2022 | 11:18h | UTCTrastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
DESTINY-Breast04: In a phase 3 trial, trastuzumab deruxtecan resulted in longer progression-free and overall survival than the physician’s choice of chemo among patients with HER2-low breast cancer. #ASCO22 https://t.co/bgheQ1yolb pic.twitter.com/nfRMcIh9Ly
— NEJM (@NEJM) June 5, 2022
Phase 2 RCT: Efficacy of epigallocatechin-3-gallate in preventing dermatitis in patients with breast cancer receiving postoperative radiotherapy.
2 Jun, 2022 | 10:34h | UTCEfficacy of Epigallocatechin-3-Gallate in Preventing Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy: A Double-Blind, Placebo-Controlled, Phase 2 Randomized Clinical Trial – JAMA Dermatology (free for a limited period)
Visual Abstract: Efficacy of Epigallocatechin-3-Gallate on Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy
Expert Analysis: Cardiotoxicity and the evolving landscape of HER2-targeted breast cancer treatment.
2 Jun, 2022 | 10:11h | UTC
ASCO Guideline Update: Systemic therapy for advanced human epidermal growth factor receptor 2–positive breast cancer.
1 Jun, 2022 | 11:38h | UTC
Commentary on Twitter
Out on JCO the latest @ASCO Guidelines Update on the treatment of HER2-positive ABC. Key points: standard first line remains THP, new second line is T-DXd, no standard after progression to T-DXd, a setting for which we urgently need data.https://t.co/2mMxBLACmf pic.twitter.com/2sXpzqz4ym
— Paolo Tarantino (@PTarantinoMD) June 1, 2022
ASCO Guideline Update: Management of advanced human epidermal growth factor receptor 2–positive breast cancer and brain metastases.
1 Jun, 2022 | 11:36h | UTC
Commentary on Twitter
? Just published in #JCO: Guideline update on management of advanced human epidermal growth factor receptor 2–positive #breastcancer and #brainmetastases.
Read more ➡️ https://t.co/fz0lfJE8zb #bcsm #btsm #brainmets pic.twitter.com/C7tyCsVGR7
— Journal of Clinical Oncology (@JCO_ASCO) May 31, 2022
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
31 May, 2022 | 10:46h | UTC
Commentary on Twitter
Online Now: Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies https://t.co/Im8F60VMjO
— Cancer Cell (@Cancer_Cell) May 27, 2022
RCT: Effect of supine vs. prone breast radiotherapy on acute toxic effects of the skin among women with large breast size.
27 May, 2022 | 11:51h | UTCEffect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Editorial: Prone Whole-Breast Radiotherapy—Better Than Supine? (free for a limited period)
Commentary on Twitter
Adjuvant breast radiotherapy in the prone position decreases acute skin toxicity in women with large breast size, as demonstrated by this multicenter randomized clinical trial. https://t.co/6Emr2Hy5KH #BCSM #RadOnc
— JAMA Oncology (@JAMAOnc) May 26, 2022
Position Paper: Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer.
26 May, 2022 | 10:42h | UTC
RCT: The addition of Metformin to standard therapy did not improve outcomes in patients with breast cancer.
25 May, 2022 | 11:49h | UTCEffect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Who Will Benefit From Metformin? – JAMA Oncology
RCT: Everolimus is not beneficial when added to adjuvant endocrine therapy in patients with high-risk hormone receptor–positive, human epidermal growth factor receptor 2–negative primary breast cancer.
25 May, 2022 | 10:57h | UTC
Commentaries on Twitter
Previously presented @myESMO VP, the #UNIRAD RCT of adjuvant everolimus in high-risk EBC is now published on @JCO_ASCO. Trial stopped for futility: everolimus didn’t improve DFS & was poorly tolerated. Large research effort answering an important question.https://t.co/wmYLWpDWTC
— Paolo Tarantino (@PTarantinoMD) May 24, 2022
Everolimus added to adjuvant ET fails to improve DFS in patients with high-risk HR+ve, HER2 neg primary breast cancer; poorly tolerated -53.4% discontinuation ratehttps://t.co/lmq2jhbhCO
— K Pavithran (@drkpavithran) May 24, 2022
RCT: Effect of Denosumab added to 2 different nab-paclitaxel regimens as neoadjuvant therapy in patients with primary breast cancer.
25 May, 2022 | 10:54h | UTCEffect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In a randomized clinical trial in 780 pts with #breastcancer, addition of denosumab to anthracycline/taxane-containing neoadjuvant chemotherapy with two different nab-paclitaxel schedules did not increase the pCR rate (41% vs 43% without denosumab): https://t.co/gPu6hrSp7z #bcsm
— NatureRevClinOncol (@NatRevClinOncol) May 24, 2022
RCT: Elacestrant (oral selective estrogen receptor degrader) vs. standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer.
20 May, 2022 | 10:55h | UTC